Abeona Therapeutics (Abeona Therapeutics) Scaled Net Operating Assets : -0.75 (As of Mar. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Abeona Therapeutics's operating assets for the quarter that ended in Mar. 2024 was $12.48 Mil. Abeona Therapeutics's operating liabilities for the quarter that ended in Mar. 2024 was $60.54 Mil. Abeona Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $64.00 Mil. Therefore, Abeona Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was -0.75.

Abeona Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Abeona Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Scaled Net Operating Assets Chart

Abeona Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.33

0.07

0.04

-0.22

-0.50

Abeona Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial															-0.22	-0.40	-0.49	-0.48	-0.75

Competitive Comparison of Abeona Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Abeona Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abeona Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Scaled Net Operating Assets falls into.

Abeona Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Abeona Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(11.776	-	43.776)	/	64.214
=	-0.50

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	64.002	-	52.226
=	11.776

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	49.176	-	4.402	-	0.998
=	43.776

Abeona Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(12.484	-	60.54)	/	64.002
=	-0.75

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	74.828	-	62.344
=	12.484

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	83.709	-	22.125	-	1.044
=	60.54

Abeona Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Abeona Therapeutics (Abeona Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (NAS:ABEO) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

PCJ:Germany PCJ:Germany

Address

1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019

Website

https://www.abeonatherapeutics.com

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.

Executives

Mark Alvino	director	C/O SCO SECURITIES LLC, 1285 AVENUE OF THE AMERICAS 35TH FLOOR, NEW YORK NY 10019
Michael Amoroso	officer: Chief Operating Officer	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Vishwas Seshadri	director, officer: Chief Executive Officer	64 STRYKER COURT, BRIDGEWATER NJ 08807
Leila Alland	director	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Christine Berni Silverstein	officer: Chief Financial Officer	C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Joseph Walter Vazzano	officer: Chief Financial Officer	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Brendan M. O'malley	officer: SVP, General Counsel	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Adage Capital Partners, L.p.	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Management, L.p.	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Partners Gp, L.l.c.	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert Atchinson	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Phillip Gross	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Edward Carr	officer: Vice President, Controller	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Todd Wider	director	4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219